HAYWARD, Calif., July 1, 2026
Arcus Biosciences, Inc. announced the publication of new translational research in Nature demonstrating a strong biological and clinical relationship between casdatifan, an investigational HIF-2α inhibitor, and treatment outcomes in patients with metastatic clear cell renal cell carcinoma (ccRCC). The study is the first to comprehensively connect clinical responses, peripheral biomarker changes, and tumor biology in patients treated with a HIF-2α inhibitor. Results from the ARC-20 study showed that deep and sustained suppression of serum erythropoietin (EPO), a downstream biomarker of HIF-2α activity, was associated with higher response rates, longer progression-free survival (PFS), and improved outcomes in patients with advanced kidney cancer who had previously received multiple standard therapies. A pooled analysis involving 121 heavily pretreated patients demonstrated a median progression-free survival of 12.2 months, highlighting the potential of casdatifan to provide durable disease control even after prior immunotherapy and VEGFR-targeted treatments.
Nature Study Validates HIF-2α Biology and EPO as a Predictive Biomarker
The published research provides compelling evidence that serum EPO suppression can serve as a reliable pharmacodynamic biomarker for monitoring HIF-2α inhibition. Investigators observed that patients achieving greater reductions in circulating EPO experienced significantly better clinical outcomes, including higher confirmed objective response rates and prolonged progression-free survival. The study also demonstrated that tumors with elevated baseline HIF-2α pathway activity, determined through gene-expression profiling and tumor EPO measurements, responded more favorably to casdatifan therapy. Researchers believe these findings establish a direct biological connection between HIF-2α-driven tumors and treatment efficacy while supporting biomarker-guided patient selection in future clinical development. According to study investigators, this represents the first comprehensive evaluation linking HIF-2α inhibition, tumor biology, circulating biomarkers, and patient outcomes within a single clinical dataset.
Casdatifan Demonstrates Durable Clinical Benefit in Heavily Pretreated Patients
Clinical findings from the pooled ARC-20 analysis further reinforced casdatifan’s therapeutic potential in advanced kidney cancer. Across four monotherapy cohorts, the investigational therapy achieved a 31% confirmed objective response rate and a median progression-free survival of 12.2 months, despite more than half of enrolled patients having received three or more prior lines of therapy. Within the Phase 3 dose cohort receiving 100 mg once daily, the confirmed response rate increased to 35%, while 60% of patients remained progression-free after 12 months. A subsequent analysis conducted in January 2026 reported that median progression-free survival for this cohort had extended to 15.1 months, further strengthening confidence in the selected Phase 3 dose. The safety profile remained manageable, with anemia and hypoxia representing the most frequently reported class-related adverse events, while treatment discontinuations due to these events remained uncommon.
Advertisement
Arcus Advances Global Development Strategy for Casdatifan
Arcus Biosciences is positioning casdatifan as a foundational therapy across multiple treatment settings for clear cell renal cell carcinoma. The company is currently advancing several clinical programs evaluating the investigational therapy as both a standalone treatment and in combination with immune checkpoint inhibitors, VEGF-targeted therapies, and tyrosine kinase inhibitors (TKIs). Enrollment is ongoing in the global Phase 3 PEAK-1 trial comparing casdatifan plus cabozantinib against cabozantinib alone in immunotherapy-experienced metastatic ccRCC patients, while an additional first-line Phase 3 study is expected to begin before the end of 2026. Arcus believes the newly published Nature research provides important biological validation for its development strategy by confirming that HIF-2α pathway suppression directly correlates with meaningful clinical benefit. If future late-stage studies confirm these findings, casdatifan could emerge as a significant new targeted therapy for patients with advanced kidney cancer across multiple lines of treatment.
Source: Arcus Biosciences press release
